93 related articles for article (PubMed ID: 2533153)
1. Zoladex: therapeutic effects in postmenopausal breast cancer.
Harris AL; Carmichael J; Cantwell BM; Dowsett M
Horm Res; 1989; 32 Suppl 1():213-6; discussion 217. PubMed ID: 2533153
[TBL] [Abstract][Full Text] [Related]
2. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
Harris AL; Carmichael J; Cantwell BM; Dowsett M
Br J Cancer; 1989 Jan; 59(1):97-9. PubMed ID: 2527049
[TBL] [Abstract][Full Text] [Related]
3. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
Nicholson RI; Walker KJ; Walker RF; Read GF; Turkes A; Robertson JF; Blamey RW
Horm Res; 1989; 32 Suppl 1():198-201. PubMed ID: 2533149
[TBL] [Abstract][Full Text] [Related]
4. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
[TBL] [Abstract][Full Text] [Related]
5. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
Robertson JF; Walker KJ; Nicholson RI; Blamey RW
Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
[TBL] [Abstract][Full Text] [Related]
6. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
[TBL] [Abstract][Full Text] [Related]
7. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
[TBL] [Abstract][Full Text] [Related]
8. Endocrinology of Zoladex in postmenopausal women.
Dowsett M; Cantwell BM; Harris AL
Horm Res; 1989; 32 Suppl 1():209-12. PubMed ID: 2533152
[TBL] [Abstract][Full Text] [Related]
9. Zoladex in advanced breast cancer.
Robertson JF; Nicholson RI; Walker KJ; Blamey RW
Horm Res; 1989; 32 Suppl 1():206-8. PubMed ID: 2533151
[TBL] [Abstract][Full Text] [Related]
10. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
Dixon AR; Robertson JF; Jackson L; Nicholson RI; Walker KJ; Blamey RW
Br J Cancer; 1990 Nov; 62(5):868-70. PubMed ID: 2147110
[TBL] [Abstract][Full Text] [Related]
11. A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist--Zoladex.
Cassano A; Astone A; Garufi C; Noviello MR; Pietrantonio F; Barone C
Cancer Lett; 1989 Nov; 48(2):123-4. PubMed ID: 2555044
[TBL] [Abstract][Full Text] [Related]
12. Medical castration with zoladex: a conservative approach to premenopausal breast cancer.
Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M; Bonadonna G
Tumori; 1991 Apr; 77(2):145-50. PubMed ID: 1828640
[TBL] [Abstract][Full Text] [Related]
13. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
Plowman PN; Nicholson RI; Walker KJ
Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
[TBL] [Abstract][Full Text] [Related]
14. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin.
Dowsett M; Cantwell B; Lal A; Jeffcoate SL; Harris AL
J Clin Endocrinol Metab; 1988 Apr; 66(4):672-7. PubMed ID: 2964454
[TBL] [Abstract][Full Text] [Related]
15. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
16. Effect of LHRH agonist, Zoladex, on ovarian histology.
Williamson K; Robertson JF; Ellis IO; Elston CW; Nicholson RI; Blamey RW
Br J Surg; 1988 Jun; 75(6):595-6. PubMed ID: 2969269
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M
Anticancer Drugs; 1992 Feb; 3(1):3-8. PubMed ID: 1535804
[TBL] [Abstract][Full Text] [Related]
18. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer.
Nicholson RI; Walker KJ; Turkes A; Dyas J; Plowman PN; Williams M; Blamey RW
J Steroid Biochem; 1985 Nov; 23(5B):843-7. PubMed ID: 2934580
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
20. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).
Bianco AR; Rosso R; Calabresi F; Fiorentino M; Lopez M; Sismondi PG; Lenti R; Fosser V; De Placido S; Perrone F
Eur J Gynaecol Oncol; 1991; 12(6):429-37. PubMed ID: 1839730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
